Trials / Completed
CompletedNCT05478499
Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2022-10-06
- Primary completion
- 2024-01-11
- Completion
- 2024-10-17
- First posted
- 2022-07-28
- Last updated
- 2025-10-28
- Results posted
- 2025-03-13
Locations
29 sites across 5 countries: United States, France, Germany, Poland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05478499. Inclusion in this directory is not an endorsement.